MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Seed amplification assay detects alpha-synuclein in cerebrospinal fluid in pre- and symptomatic autosomal dominant Alzheimer’s disease

    A. Ahuja, J. Ringman, K. Wong (Los Angeles, USA)

    Objective: To examine the ability to detect concurrent Lewy Body Disease via Lew Body pathology (LBP) in Autosomal Dominant Alzheimer’s Disease (ADAD) through detection of…
  • 2025 International Congress

    Atypical Frontotemporal Dementia with Parkinsonism Linked to SQSTM1 Mutation A Clinicopathological Case Study

    C. Espinoza Vinces, M. Zelaya Huerta, V. Coca Pueyo, G. Montoya Murillo, A. Patiño García, R. Villino Rodríguez, A. Atorrasagasti Villar, J. Arbizu, M. Riverol (Pamplona, Spain)

    Objective: To describe the clinical, neuroimaging, and neuropathological features of a patient with frontotemporal dementia (FTD) and parkinsonism related to mutation in the SQSTM1 gene.…
  • 2025 International Congress

    Natural history and epidemiological study of multiple system atrophy in Hokkaido: HoRC-MSA 2014-2025

    M. Matsushima, K. Sakushima, Y. Kanatani, N. Nishimoto, J. Sawada, T. Matsuoka, H. Uesugi, N. Minami, K. Sako, A. Takei, S. Hisahara, A. Tamakoshi, N. Sato, I. Yabe (Sapporo, Japan)

    Objective: To investigate epidemiological information of multiple system atrophy (MSA) patients in Hokkaido, Japan by using the registry data from the Hokkaido Rare-disease Consortium for…
  • 2025 International Congress

    Assessing Disease Progression in MSA: Development of a Bayesian Progression Model

    J. Wiedemann, C. Ebbesen, T. Jensen, M. Quintana, B. Wendelberger, W. Poewe, F. Krismer, S. Zanigni, J. Luthman (Valby, Denmark)

    Objective: Develop a Bayesian progression model (BPM) for MSA that leverages individual-level data derived from long-term follow up and offers a clinically interpretable, slope-based primary…
  • 2025 International Congress

    Quantitative Gait Evaluation in Multiple System Atrophy: Supervised versus Unsupervised Analysis

    F. Marchand, J. Labreuche, T. Ollivier, D. Guehl, A. Delval, L. Defebvre, AK. Berger, J. Wiedemann, L. Kjaersgaard, T. Warlop, A. Fasano, BR. Bloem, D. Devos, C. Moreau (Lille, France)

    Objective: This study aims to compare gait parameters in real-world (RW) home settings with supervised clinical assessments on 6-minutes walking test (6MWT) in MSA patients…
  • 2025 International Congress

    Association between Imaging Glymphatic Dysfunction Markers and Clinical Symptoms in Progressive Supranuclear Palsy

    J. Pardo, C. Martín-Barceló, C. Falcon, R. Sala-Llonch, I. Roura, A. Campabadal, N. Bargalló, C. Painous, M. Fernández, O. Brengaret, C. Brenlla, A. Cámara, E. Muñoz, F. Valldeoriola, MJ. Martí, Y. Compta, C. Junqué, B. Segura (Barcelona, Spain)

    Objective: This study aims to explore possible glymphatic dysfunction using diffusion tensor image analysis along the perivascular space (DTI-ALPS) in patients with progressive supranuclear palsy…
  • 2025 International Congress

    Oxidative stress in Progressive Supranuclear Palsy

    P. Alster, D. Otto-ślusarczyk, M. Struga, N. Madetko-Alster (Warsaw, Poland)

    Objective: The goal of the study is to evaluate the significance of oxidative stress in the examination and pathophysiology of Progressive Supranuclear Palsy (PSP). Additionally,…
  • 2025 International Congress

    Exploring Cardiac Autonomic Dysfunction in Synucleinopathies with Parkinsonism Across Awake-Sleep Stages

    N. Limotai, T. Somboon, S. Rujirussawarawong, T. Tumnark, N. Suanprasert, N. Unwanatham, C. Limotai (Bangkok, Thailand)

    Objective: To explore the differences in heart rate variability (HRV) across awake-sleep stages between patients with synucleinopathies and elderly controls without parkinsonism Background: A complex…
  • 2025 International Congress

    Safety, Tolerability and Pharmacokinetics of a Novel Oral OGA Inhibitor (FNP-223) First-in-Human Phase 1 Study

    R. Pokorny, J M. Ryan, K. Abd-Elaziz, C. Varona, M. Schneider, C. Wiessner, J F. Stallaert, B. Permanne, A. Quattropani, D. Beher (Lausanne, Switzerland)

    Objective: To evaluate the safety, tolerability, and pharmacokinetics of FNP-223 (formerly ASN90) in healthy volunteers (HV). Background: Proteinopathies remain largely untreatable and novel therapies are…
  • 2025 International Congress

    GNAI1-Associated Childhood-Onset Hyperkinetic Movement Disorder: A Case Report

    T. Larsh, A. Espay, D. Gilbert, S. Wu (Cincinnati, USA)

    Objective: To describe the clinical presentation, diagnostic evaluation, and genetic findings in a 7-year-old male with a hyperkinetic movement disorder associated with a novel GNAI1…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 181
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley